Radioiodine treatment of differentiated thyroid cancer related to guidelines and scientific literature
Por:
Estorch M, Mitjavila M, Muros MA and Caballero E
Publicada:
1 may 2019
Ahead of Print:
7 feb 2019
Categoría:
Radiology, nuclear medicine and imaging
Resumen:
In differentiated thyroid cancer (DTC), radioiodine is administered to eliminate residual normal thyroid tissue after thyroidectomy (ablative treatment), to treat residual microscopic disease (adjuvant treatment), and to treat macroscopic or metastatic disease. Currently, treatment of DTC with I-131 is still a matter of controversy due to the absence of prospective clinical trials assessing its benefit in terms of overall survival and recurrence-free interval. The current recommendations of the experts are based on observational retrospective data and on their interpretation of the literature. Pending the results of the prospective trials that are currently underway, the use of I-131 seems to be justified not only in high-risk patients, but also in intermediate-risk and low-risk patients. The guidelines of The American and British Thyroid Association, European and American Societies of Nuclear Medicine, The European Consensus Group and the latest edition of National Comprehensive Cancer Network (NCCN) were considered in drawing up this continuing education document, we also undertook a review of the related scientific literature. (C) 2019 Published by Elsevier Espafia, S.L.U. on behalf of Sociedad Espafiola de Medicina Nuclear e Imagen Molecular.
Filiaciones:
Estorch M:
Servicio de Medicina Nuclear, Hospital de la Santa Creu i Sant Pau, Barcelona, España
Mitjavila M:
Servicio de Medicina Nuclear, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, España
Muros MA:
Servicio de Medicina Nuclear, Hospital Universitario Virgen de las Nieves, Granada, España
:
Servicio de Medicina Nuclear, Hospital Doctor Peset, Valencia, España
|